Table 4.
Validation of the cutoffs developed in Group A in the subset of OSCCa from the previous cohort (Group B)
| Number of patients (n = 119) | 5-year OSb % | Log-rank P value | HRc (95% CId) | P value | |
|---|---|---|---|---|---|
| Neutrophils1 | |||||
| ≤ 4.8 | 70 | 60.8 | < 0.001 | 1 | 0.002 |
| 4.8–9.1 | 47 | 37.7 | 1.578 (0.984–2.531) | ||
| ≥ 9.1 | 2 | 0.0 | 11.387 (2.622–49.448) | ||
| Monocytes1 | |||||
| ≤ 0.3 | 8 | 62.5 | 0.314 | 1 | 0.321 |
| > 0.3 | 111 | 49.8 | 1.797 (0.565–5.712) | ||
| Lymphocytes1 | |||||
| ≤ 0.8 | 1 | 0.0 | 0.250 | 1 | 0.275 |
| > 0.8 | 118 | 51.1 | 0.330 (0.045–2.413) | ||
| NLRe | |||||
| ≤ 2.9 | 76 | 65.3 | < 0.001 | 1 | < 0.001 |
| 2.9–5.7 | 39 | 27.2 | 2.382 (1.465–3.871) | ||
| ≥ 5.7 | 4 | 0.0 | 7.815 (2.644–23.098) | ||
| SIRIf | |||||
| ≤ 1.0 | 33 | 69.7 | < 0.001 | 1 | < 0.001 |
| 1.0–1.9 | 46 | 59.8 | 1.292 (0.677–2.464) | ||
| ≥ 1.9 | 40 | 24.0 | 3.069 (1.655–5.691) | ||
a-
OSCC: oral cavity squamous cell carcinoma;
b-
OS: overall survival;
c-
HR: hazard ratio;
d-
CI: confidence interval;
e-
NLR: neutrophil-to-lymphocyte ratio;
f-
SIRI: Systemic Inflammation Response Index.
1:
: Units × 109/L